Patents by Inventor Yan-Ling Zhang
Yan-Ling Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230143552Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.Type: ApplicationFiled: October 7, 2022Publication date: May 11, 2023Applicants: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Luka Dordevic, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Patent number: 11572368Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: GrantFiled: August 11, 2016Date of Patent: February 7, 2023Assignees: The General Hospital Corporation, The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Patent number: 11498896Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.Type: GrantFiled: March 20, 2020Date of Patent: November 15, 2022Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Luka Dordevic, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Patent number: 11377423Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.Type: GrantFiled: August 16, 2017Date of Patent: July 5, 2022Assignees: The Broad Institute, Inc., The General Hospital CorporationInventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
-
Publication number: 20210147355Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.Type: ApplicationFiled: March 20, 2020Publication date: May 20, 2021Applicants: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Luka Dordevic, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Patent number: 10752588Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.Type: GrantFiled: December 18, 2015Date of Patent: August 25, 2020Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier, Michel Weiwer, Edward Scolnick, Michelle Palmer, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Publication number: 20200256880Abstract: This disclosure relates to methods of detecting and quantifying neuronal activation. This disclosure further relates to a particular phosphorylation of calcineurin A alpha (CNA?) at serine 469 (S469) of the amino acid sequence of the protein as a marker for neuronal activation, antibodies recognizing that phosphorylated form of CNA?, and uses of such antibodies, for example, in various neuronal activity assays and related kits.Type: ApplicationFiled: August 16, 2018Publication date: August 13, 2020Inventors: Li Li, Yan-Ling Zhang, Ayan Ghoshal, Jeffrey Cottrell
-
Patent number: 10662199Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: GrantFiled: October 17, 2017Date of Patent: May 26, 2020Assignees: The Broad Institute, Inc., The General Hospital Corporation, Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Publication number: 20200153844Abstract: A method may be performed using a server. The method may include receiving an identity authentication request associated with a user, generating authentication information based on the identity authentication request, and generating candidate information based on the authentication information such that the authentication information is a subset of the candidate information. The candidate information may be displayed at a randomly selected location. The user may provide input through a graphic input interface to select the authentication information from among the candidate information.Type: ApplicationFiled: December 10, 2019Publication date: May 14, 2020Inventors: Yan Ping TANG, Yan Ling ZHANG, Yu Ye WANG, Ling GONG, Jia Qi HUANG, Ren Jia WEI
-
Patent number: 10633336Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.Type: GrantFiled: December 18, 2015Date of Patent: April 28, 2020Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Luka Dordevic, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Patent number: 10626438Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).Type: GrantFiled: December 5, 2017Date of Patent: April 21, 2020Assignee: The Broad Institute, Inc.Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
-
Publication number: 20190345105Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.Type: ApplicationFiled: December 18, 2015Publication date: November 14, 2019Applicants: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Publication number: 20190023656Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.Type: ApplicationFiled: December 18, 2015Publication date: January 24, 2019Applicants: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Publication number: 20180155283Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopammode inergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.Type: ApplicationFiled: December 18, 2015Publication date: June 7, 2018Applicants: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Luka Dordevic, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
-
Publication number: 20180155760Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1 ??(Formula I).Type: ApplicationFiled: December 5, 2017Publication date: June 7, 2018Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
-
Publication number: 20180099977Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: October 17, 2017Publication date: April 12, 2018Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Publication number: 20180072671Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.Type: ApplicationFiled: August 16, 2017Publication date: March 15, 2018Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
-
Patent number: 9890172Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: GrantFiled: May 5, 2016Date of Patent: February 13, 2018Assignees: The Broad Institute, Inc., The General Hospital CorporationInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Stephen J. Haggarty, Yan-Ling Zhang
-
Publication number: 20180016282Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: August 11, 2016Publication date: January 18, 2018Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Patent number: 9856509Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).Type: GrantFiled: May 1, 2014Date of Patent: January 2, 2018Assignee: The Broad Institute, Inc.Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner